9-11th December 2025 | London, UK

www.cell-engager-europe.com

REGISTER BY FRIDAY, 19TH SEPTEMBER & SAVE UP TO £1,100



T-Cell Engager Therapeutics Summit EUROPE

Optimise Targeting, Reduce On-Target Off-Tumour Toxicities & Accelerate Immunotherapies

Uniting European Cell Engager & Bispecific Antibody Leaders to Optimise Targeting, Safety & Translational Research in Oncology & Autoimmune Indications

Expert Speakers Include:

Petra Lutterbuese
Principal Scientist
Amgen

Nicolas Sabarth
Head, Research Laboratory Biotherapeutics Discovery & Cancer Immunology
Boehringer Ingelheim

Jeff Jones
Chief Medical Officer
Cullinan Therapeutics

Sarah Missel
Vice President, Bispecifics Portfolio Development
Immatics

Uli Bialucha
Chief Scientific Officer
Xilio Therapeutics

Kara Olsen
Fellow Scientist
Regeneron

> It was great to have many opportunities to network with folks. I especially enjoyed the breadth and quality of the talks
>
> **Boehringer Ingelheim**

+44 (0)20 3141 8700 info@hansonwade.com
www.cell-engager-europe.com

hansonwade

Welcome to the T-Cell Engager Therapeutics Summit Europe

T-Cell Engager Therapeutics Summit EUROPE
9-11th December 2025 | London, UK

A wave of 8 TCE approvals has catalysed an influx of multimillion-euro investment and M&A activity in TCEs, such as **Xilio** receiving $2.1billion from **AbbVie** to accelerate novel TCEs for immuno-oncology including masked TCEs and Innate Pharma securing €15 million from **Sanofi**. Pharma and biotech are staking their claims on the next generation of immunotherapies here at the **T-Cell Engager Therapeutics Summit Europe**.

However, with challenges in target selection and translational research to optimise immunogenicity, improve bioavailability, and increase the therapeutic window, in addition to opportunities to expand into the exciting potential in autoimmune indications, it's essential to unite the growing community of European industry leaders to stay ahead of the curve and accelerate therapies to the clinic.

Following the success of our Boston meeting, the **T-Cell Engager Therapeutics Summit Europe** is the first forum to bring together European-based cell engager experts in **Preclinical**, **Translational**, **Immunology**, **Biology** and more to successfully translate preclinical findings to the clinic and beyond.

With leading case studies in identifying novel tumour targets, enhancing durability, optimising dosing for first-in-human studies, and expanding into autoimmune diseases, join 70+ European pioneers from **AstraZeneca**, **Amgen**, **Immunocore**, **Boehringer Ingelheim**, **Immatics** and more to progress safer and more effective TCEs in oncology and autoimmune indications, and reshape immune therapy drug development.

What Previous T-Cell Engager Therapeutics Summit Attendees Had to Say

"The conference was hyper focused and really provided a good sense of what the current cell engager landscape was. I also appreciated the directed networking time and felt that with such a small group it was easy to get to know people and learn about what is in the pipeline"

InhibRx

"It was great to have many opportunities to network with folks. I especially enjoyed the breadth and quality of the talks"

Boehringer Ingelheim

Key Benefits of Attending

Supercharge TCEs with Co-Stimulation

Hear from **Regeneron** and **Zymeworks** on combining TCEs with **CD28**, **CD137**, or **CD2** agonists to enhance **T cell fitness**, optimise **co-stimulatory target selection**, and maximise affinity for stronger cytotoxic responses.

Advance Logic-Gated & Conditional TCE Designs

Learn from **Xilio** and others how **tumour microenvironment–responsive formats** are driving greater tumour specificity and preventing escape from antigen-negative clones.

Unlock TCEs in Autoimmune Diseases

Gain exclusive clinical and preclinical insights from **Cullinan**, **IN8Bio**, and **Cue Biopharma**. Compare design and trial considerations in oncology vs autoimmunity and explore strategies to target **B cell subsets** and **pathogenic cell types** for next-generation therapeutics.

Overcome Preclinical Limitations

Join experts from **Amgen**, and **NovalGen** to address challenges such as **hyperactivated T cells** and **unrealistic tumour clearance**. Hear first-hand from **NovalGen** on preventing **T cell exhaustion** with their pioneering **AutoRegulation platform**.

Expand Beyond Traditional TCEs

Explore innovative modalities, from **AstraZeneca's TITAN** (Target Induced T-cell Activating Nanobodies), **BIOMUNEX's MAIT engagers**, to **Peipp's labs NK cell engagers** advancing novel dual and multi-targeting approaches.

+44 (0)20 3141 8700 info@hansonwade.com
www.cell-engager-europe.com
hansonwade

What's New For 2025?

T-Cell Engager Therapeutics Summit EUROPE
9-11th December 2025 | London, UK

Key Sessions not to Miss

Leveraging TCR-Based and TCR-Mimetic Bispecifics to Overcome Specificity & Density Challenges in Solid Tumours
Kate Atkin, Associate Director, **Immunocore**

1

T-Cell Engager Therapies: Addressing Challenges & Advancing Next-Generation Approaches
Nicolas Sabarth, Head, Research Laboratory Biotherapeutics Discovery & Cancer Immunology, **Boehringer Ingelheim**

2

ATACR and SEECR: Tumour-activated T-Cell Engagers Designed to Drive Potent Synthetic Anti-Tumour Immunity
Uli Bialucha, Chief Scientific Officer, **Xilio Therapeutics**

3

Investigating Preclinical Safety Assessments of Dual AND-Gated TCEs with AMG 305
Petra Lutterbuese, Principal Scientist, **Amgen**

4

Interactive Workshop Discussion: Co-Stimulation

Supercharging T-Cell Engager Efficacy with Co-Stimulation: Formats, Targets & Strategies to Achieve Durable Responses with Improved Potency & Avidity

This high-impact strategy workshop brings together pioneering T-cell engager experts to tackle which co-stimulatory receptor to target, how to time activation signals, and whether to build into a single trispecific or deliver sequentially. Get closer to optimising co-stimulatory target selection, and maximising affinity for stronger cytotoxic responses.

Kara Olsen
Research Fellow
Regeneron

Nina Weisser
Director, Multispecific Antibody Therapeutics
Zymeworks

Companies at our First European Forum 2025

AMGEN | AstraZeneca | Boehringer Ingelheim | IMMUNOCORE | REGENERON | Roche

Showcase Your Scientific Poster

This is an informal session to help you connect with your peers in a relaxed atmosphere and forge new and beneficial relationships. With an audience of cell engager experts eager to hear the latest innovations and positive movement, you will have the opportunity to display a poster presenting your own work.

Register your place to submit an abstract for review to showcase your poster*

*Please visit the website for the T&Cs for presenting a poster

+44 (0)20 3141 8700 info@hansonwade.com
www.cell-engager-europe.com

hansonwade

Your Expert Speakers

Large Pharma:

Petra Lutterbuese
Principal Scientist
Amgen

Christopher Lloyd
Director
AstraZeneca

Nicolas Sabarth
Head, Research Laboratory Biotherapeutics Discovery & Cancer Immunology
Boehringer Ingelheim

Kara Olson
Fellow Scientist
Regeneron

Sara Colombetti
Head, Global Department
Roche

Pioneering Biotech:

Simon Plyte
Chief Scientific Officer
BIOMUNEX

Steven Quayle
Senior Vice President & Head, Research & Translational Medicine
Cue Biopharma

Jeff Jones
Chief Medical Officer
Cullinan Therapeutics

Alfred Lim
Director, Lab Research
Etcembly

Sarah Missel
Vice President, Bispecifics Portfolio Development
Immatics

Kate Atkin
Associate Director
Immunocore

Kate Rochlin
Chief Operating Officer
IN8Bio

Sara Majocchi
Project Director
Light Chain Biosciences

Marcela Guzman
Senior Director & Head, *In Vitro* Pharmacology
Molecular Partners

David Granger
Vice President, Research & Development
NovalGen

Thomas Andresen
Chief Executive Officer
T-Cypher Bio

Uli Bialucha
Chief Scientific Officer
Xilio Therapeutics

Nina Weisser
Director, Multispecific Antibody Therapeutics
Zymeworks

Academic KOLs:

Ken Howard
Associate Professor
Aarhus University

Matthias Peipp
Professor
University of Kiel

Pre-Conference Workshop Day
Tuesday, 9th December

T-Cell Engager Therapeutics Summit EUROPE
9-11th December 2025 | London, UK

Morning Coffee and Check-In 8.00

Workshop A 9.00

Emerging Clinical & Regulatory Insights to Inform Development Strategy in Autoimmune Clinical Trails

As T-Cell Engager developers look beyond oncology into the complex landscape of autoimmune disease, the rules of safety, dosing, and trial design change dramatically. This interactive workshop will equip you with the critical clinical, translational, and regulatory insights needed to navigate these uncharted waters. Learn how to optimise dosing and prophylaxis to minimize CRS and neurotoxicity, manage the unique risks of B cell targeting and T cell activation in dysregulated immune systems, and adapt your molecule design and trial strategy for success across indications. If you're planning to bring your TCE program into autoimmune disease, this is the must-attend strategy session to future-proof your clinical development pathway.

This workshop will cover:

- **Key lessons from clinical T-Cell Engager trials** – recurring safety, efficacy, and translational challenges, and how to proactively address data gaps to improve later-stage success
- **Optimising dosing and prophylaxis** – strategies to mitigate CRS, neurotoxicity, and other immune-related toxicities, with comparison of tolerability thresholds between oncology and autoimmune disease settings
- **Oncology vs. autoimmune disease differences** – impact of B cell targeting and T cell activation dynamics, including risks of stimulating hypoactive or hyper-excitable T cells in autoimmune patients
- **Translational and regulatory considerations for FIH studies** – integrating preclinical insights, model limitations, and risk mitigation strategies to meet safety and regulatory requirements
- **Tailoring molecular and trial design across indications** – adapting formats, mechanisms, and study designs for oncology versus autoimmune disease, and best practices for engaging regulators on cross-indication programs

Workshop Leader

Jeff Jones
Chief Medical Officer
Cullinan Therapeutics

Lunch Break 12.00

Workshop B 1.00

Supercharging T-Cell Engager Efficacy with Co-Stimulation: Formats, Targets & Strategies to Achieve Durable Responses with Improved Potency & Avidity

As T cell engagers push into solid tumours and earlier-line settings, co-stimulation has emerged as one of the most promising levers for boosting efficacy and durability. This high-impact strategy workshop brings together pioneering T-cell engager experts to tackle which co-stimulatory receptor to target, how to time activation signals, and whether to build into a single trispecific or deliver sequentially. You'll gain practical, actionable insights on overcoming tumour microenvironment barriers, managing exhaustion, and minimising safety risks. If you're serious about engineering next-generation TCEs that deliver long-lasting responses, this is the must-attend session to get ahead of the curve.

This workshop will cover:

- **Clarifying the biological rationale** – How co-stimulatory domains (CD28, CD137, CD2 etc.) enhance T cell fitness, prevent early exhaustion, and improve anti-tumour activity and aligning primary CD3 activation with co-stimulation signals to maximise efficacy and avoid mismatched signalling
- **Choosing the right co-stimulatory target** – Comparative advantages, limitations, and clinical unknowns for different T-cell engager targets
- **Design and delivery strategies** – How linking co-stimulatory elements directly to the engager can optimise timing, localisation, and therapeutic effect
- **Managing exhaustion and safety risks** – Avoiding on-target/off-tumour risks by activation of non-tumour T cell subsets, reducing CRS, and limiting Fc-mediated toxicity
- **Combinations vs trispecifics** – Comparing strategies, advantages, and limitations – looking at clinical data

Workshop Leaders

Kara Olsen
Research Fellow
Regeneron

Nina Weisser
Director, Multispecific Antibody Therapeutics
Zymeworks

End of Workshop Day 4.00

Conference Day One
Wednesday, 10th December

8.00 **Morning Coffee & Check-In**

8.55 **Chair's Opening Remarks**

Overview of the Landscape of Cell Engager Therapies & Engineering Cell Engagers with a Deeper Biological Understanding

9.00 **T-Cell Engager Therapies: Addressing Challenges & Advancing Next-Generation Approaches**

Nicolas Sabarth
Head, Research Laboratory Biotherapeutics Discovery & Cancer Immunology
Boehringer Ingelheim

- Tackling key hurdles in TCE development including target discovery, safety concerns, T-cell exhaustion, and limited response rates to improve clinical outcomes despite TCEs being a clinical validated concept
- Overviewing next-generation approaches, such as co-stimulation, TCR mimics, masked TCEs, and engagement of alternative cell types - aim to unlock novel targets, enhance tumour selectivity, and enable differentiated mechanisms of action (MoA)
- Showcasing Boehringer Ingelheim's progress in advancing TCE technologies toward safer, more effective translation

Tackling On-Target, Off-Tumour Toxicity in T-Cell Engager Therapies: Engineering T-Cell Engagers for Specificity & Target Selection

9.30 **Addressing Intracellular Targets in Oncology: The PRAME TCER™ Journey**

Sarah Missel
Vice President Bispecifics Portfolio
Immatics

- Engaging PRAME peptide–HLA complexes
- Optimising TCE format and design for intracellular pHLA targeting to maximise potency, specificity, manufacturability and half-life
- Efficiently translating preclinical findings into clinical results

10.00 **Morning Break & Speed Networking**

Kickstart new connections in this speed networking session designed to help you meet a high volume of fellow cell engager experts, exchange insights, and set the stage for deeper conversations throughout the summit.

11.00 **A TCR and TCR-mimetic Discovery Platform for Targeting Diverse Peptide-HLA Complexes**

Kate Atkin
Associate Director
Immunocore

- Unlocking high tumour specificity with TCR-based bispecifics – exploring how targeting peptide–HLA complexes enables precision beyond surface tumour-associated antigens (TAAs), while addressing the challenge of low epitope density
- Understanding the expression threshold – evaluating how TCR affinity and antigen presentation levels impact engagement, efficacy, and safety, with learnings from TCR-engineered therapies like tebentafusp
- Pushing beyond monoclonal limits – discussing the role of TCR-mimetics and dual-targeting strategies to improve on-target precision, reduce off-tumour effects, and broaden addressable patient populations

11.30 **Understanding the Fundamentals of Target Selection and Challenges Associated with Engineering TCR/TCRm Affinity/Specificity in pHLA Targeting**

Thomas Andresen
Chief Executive Officer
T-Cypher Bio

- Exploring untapped opportunities in both canonical and "dark antigen" spaces to offer substantial new opportunities for cancer patients
- Comparing pHLA epitope targeting with antibody-based surface antigen targeting to assess therapeutic quality and patient benefit
- Enhancing engineering precision in TCR/TCRm affinity and specificity to safely and effectively target pHLA with maximal clinical impact

Conference Day One
Wednesday, 10th December

12.00 Lunch Break

Beyond Traditional T Cells & Cell Engagers: Exploring TITAN Formats, NK Cell, MAIT Engagers, Tregs & More

Christopher Lloyd
Director
AstraZeneca

13.00 Engineering Effector CD8 Biased T-Cell Engagers with TITAN: A Novel TCE Format

- Bispecific T-cell engagers (TCEs) have shown promising efficacy in the clinic, especially in the context of hematological malignancies but recently also for small cell lung cancer
- However, these treatments are still associated with significant toxicities, including cytokine release syndrome and ICANS, limiting their therapeutic window and potential for clinical combinations
- We developed a novel TCE format, TITAN (Target Induced T-cell Activating Nanobodies), with the potential for an improved therapeutic index by engineering a first-in-class CD8-guided TCE

Simon Plyte
Chief Scientific Officer
BIOMUNEX

13.30 MAIT Engagers: Bypassing Treg Suppression & CRS in Solid Tumours

- Exploring how MAIT Engagers selectively activate cytotoxic T cells without engaging $CD4^+$ regulatory T cells, preventing tumour-localised immune dampening
- Preventing CRS without CD4 binding – discussing how MAIT Engagers are designed to prevent systemic immune overstimulation by avoiding broad T cell activation
- Redefining T cell redirection – as a next-gen alternative to CD3-based approaches, seeing how MAIT Engagers offer a strategic leap in precision, potency, and safety in immune-oncology

14.00 Afternoon Break & Poster Session

This is an informal session to help you connect with your peers in a relaxed atmosphere and forge new and beneficial relationships. With an audience of cell engager experts eager to hear the latest innovations and positive movement, you will have the opportunity to display a poster presenting your own work.

Matthias Peipp
Professor
University of Kiel

15.00 Activating NK Cell Receptors as Trigger Molecules for Bispecific Antibodies to Enhance Anti-Tumour NK Cell Responses

- Evaluating preclinical case studies of NKG2D or NKp30 engaging bispecific antibodies
- Synergy with FcγRIIIA engagement – discussing multispecific molecules and impact of molecule architecture vs combination approaches to improve synapse quality and PK profile
- Exploring opportunities for combination with adoptive NK cell transfer using a novel NK cell expansion technology for enhanced therapeutic impact

Multispecifics & Bispecifics in T-Cell Engager Design, Redefining Precision, Potency & Overcoming Exhaustion in Solid Tumours

Ken Howard
Associate Professor, Group Leader
Aurhus University

15.30 Multifunctional Biomolecular Assemblies: Nucleic Acid & Chemical Conjugation Modular Designs

- Description of a multifunctional platform using albumin as a scaffold for assembly of functionalised nucleic acid modules or chemical conjugation for combinatorial T-cell engager designs
- The incorporation of albumin sequences with different FcRn affinity for programmable pharmacokinetics of T-cell engagers
- Discussing how these synthetic combinatorial formats approaches may accelerate therapeutic prototyping and allow flexible integration of targeting and effector domains compared to traditional protein engineering

Conference Day One
Wednesday, 10th December

Sara Majocchi
Discovery Program Leader
Light Chain Bioscience

16.00 Overcoming Limitations of T-Cell Engagers with Bispecifics Providing Costimulatory Signals

- The use of molecules capable of activating the immune system by targeting costimulatory signals on T cells has not been fully explored yet
- NI-4101 is a FcRH5xCD28 bispecific antibody which has the potential to expand the number of patients who benefit from TCE-based therapies, possibly leading to deeper and more durable responses
- NI-3201, a PD-L1xCD28 bispecific antibody, additionally blocks the PD-L1/PD-1 immune checkpoint pathway, thus overcoming two major immune suppression mechanisms at once

Alfred Lim
Director, Lab Research
Etcembly

16.30 Designing Potent TCR-based T-Cell Engagers for Cancer Immunotherapy with Generative AI

- Applying our proprietary machine learning platform, EMLy, for TCR discovery leading and affinity enhancement, leading to the development of potent and safe TCR-based T-cell engagers
- Leveraging AI to optimise multi-specific modalities, to enhance immune activation and efficacy against solid tumours
- Integrating AI in the design phase to improve solubility, reduce aggregation, and boost protein yield, ensuring candidate molecules are both potent and manufacturable at scale

17.00 Chair's Closing Remarks

17.35 End of Conference Day One

"Enjoyed meeting with others who work in the same field and discussing opportunities and challenges with them"

Pfizer

"Enjoyed the high level of engagement on a breadth of topics spanning phases of discovery to late stage clinical development of immune cell engagers"

AbbVie

Conference Day Two
Thursday, 11th December

8.00 **Morning Coffee & Check-In**

8.55 **Chair's Opening Remarks**

Bridging the Preclinical Gap for T-Cell Engagers: Exploring the Limitations of Current Preclinical Models for Improved Predictivity & Clinical Safety

Petra Lutterbuese
Principal Scientist
Amgen

9.00 **Investigating Preclinical Safety Assessments of Dual AND-Gated TCEs with AMG 305**

- Preclinical development of a dual-targeting T-Cell Engager (TCE) – AMG 305
- Leveraging different techniques in a weight of evidence (WoE) approach to uncover target colocalisation in normal human tissues
- Challenges with relevant species determination for AND-gated targets

Sara Colombetti
Head, Global Department
Roche

9.30 **Uncovering the Translational Value of Humanized Mouse Models for T-Cell Engager Development**

- Enhancing translational predictability – Explore how humanized mouse systems can capture key pharmacodynamic changes, immune activation patterns, and tumor microenvironment dynamics to better forecast T-cell engager efficacy in patients
- Bridging the gap to clinical outcomes – Discuss how these models inform dose selection, immune trafficking, and safety readouts, while recognizing current limitations in replicating complex human immune biology
- Toward smarter preclinical workflows – Learn strategies to combine humanized in vivo models with patient-derived ex vivo platforms, advancing more predictive translational frameworks that reduce attrition and accelerate clinical success

10.00 **Morning Break**

David Granger
Vice President, Research & Development
NovalGen

10.30 **Pioneering AutoRegulation to Facilitate the Development of Next Generation Smart Immunotherapies with an Autonomous Self-Regulating Capability: A Preclinical & Translational Assessment**

- Addressing how TCEs are showing great efficacy in clinic but remain toxic hindering broader patient access and community use
- Showcasing NovalGen's AutoRegulation (AR) platform: safeguarding potency and efficacy while preventing T cell exhaustion through built-in self-regulation
- Advancing the world's first AR-enabled TCE toward the clinic by end of 2025

Conference Day Two
Thursday, 11th December

11.00 Panel Discussion: Bridging Bench & Bedside for T-Cell Engagers: Translational Strategies, Target Selection & Rational Design in Oncology & Autoimmunity

This expert-led discussion will unpack the unique translational challenges and opportunities for T-cell engagers across oncology and autoimmune indications. Panelists will explore how emerging scientific insights, target biology, and mechanistic understanding can inform smarter therapeutic design, combination strategies, and clinical development pathways for both cytotoxic and tolerability-driven indications.

- How does target biology influence format selection, CD3 affinity tuning, and tissue-selective delivery approaches in solid tumours vs autoimmune tissues?
- What translational tools (e.g., biomarkers, PD readouts, in vitro/in vivo models) are proving most predictive for efficacy and safety in both therapeutic areas?
- What combination strategies are most promising e.g., with checkpoint inhibitors, cytokines, or tolerance-inducing agents and how do we time them?
- Where are current translational models falling short, and how can we better model immune engagement, off-tumour effects, and chronic exposure?
- How do we de-risk multi-targeting and immune activation in non-lethal diseases where tolerance, durability, and safety thresholds differ from oncology?

Marcela Guzman Ayala
Senior Director & Head, *In Vitro* Pharmacology
Molecular Partners AG

Nina Weisser
Director, Multispecific Antibody Therapeutics
Zymeworks

12.00 Lunch Break

Exploring Conditional Activation & Masking Strategies with T-Cell Engagers for Tumour Selectivity, Reduced Toxicity & Safe Cleaving Strategies

Uli Bialucha
Chief Scientific Officer
Xilio Therapeutics

13.00 ATACR & SEECR: Tumour-Activated T-Cell Engagers Designed to Drive Potent Synthetic Anti-Tumour Immunity

- Unlock the potential of masked TCEs with Xilio's tumor-activation platform, designed to deliver potent, localised T cell activation while minimising systemic toxicities and widening the therapeutic index
- Explore next-generation ATACR bispecifics with masked CD3 domains and SEECR tri-specifics incorporating co-stimulatory signaling engineered to enhance T cell potency, persistence, and anti-tumor activity
- Gain insights into Xilio's pipeline of wholly-owned masked TCE programs targeting PSMA, CLDN18.2, and STEAP1, advancing toward clinical translation across solid tumor indication

Marcela Guzman Ayala
Senior Director & Head, *In Vitro* Pharmacology
Molecular Partners AG

13.30 AND-Gated Switch-DARPins T-Cell Engager with Co-Stimulation for Safer, More Durable Anti-Tumour Immunity

- Selective Tumour Targeting: Conditional Switch-DARPin selectively induces T cell cytotoxicity against dual-TAA expressing tumour cells, sparing single-antigen-expressing cells
- Enhanced T Cell Function: CD2 co-engagement promotes sustained T cell proliferation and prevents T cells dysfunction, supporting durable antitumour responses
- Favorable Safety Profile: *In vivo* and human whole blood studies show significant tumour regression with minimal cytokine release, highlighting the potential for safe, logic-gated immune activation

Conference Day Two
Thursday, 11th December

14.00 **Afternoon Break**

Transitioning From Oncology to Autoimmunity & Decoding Immunogenicity for T-Cell Engagers

Steven Quayle
Senior Vice President & Head, Research & Translational Medicine
Cue Biopharma

14.30 **Development of Novel Biologics that Promote T Cell-Mediated Depletion of Pathogenic Cell Types in Autoimmune Disease**

- Introduction to the Immuno-STAT™ platform for selective regulation of antigen-specific T cells
- Lead candidate CUE-501 differentiates from pan-TCEs by selectively engaging existing virus-specific T cells to deplete pathogenic B cells while minimising systemic immune activation and CRS risk
- The modularity of the Immuno-STAT™ platform enables opportunities to target additional pathogenic cell types beyond B cells and opens avenues for novel therapeutic approaches in autoimmunity and oncology

Kate Rochlin
Chief Operating Officer
IN8Bio

15.00 **Activating the Potential of Gamma Delta T-Cells in Preclinical Models: A Next-Generation Strategy to Minimise CRS & Rethink TCE Safety in Autoimmunity**

- Introduction to the potential of gamma delta T-cells and tackling the challenge of their limited presence in patients by engineering engagers that expand and activate these cells *in vivo* without relying on CD3 stimulation
- Exploring ways to safely increase levels of rare immune cells like gamma delta T-cells and NK cells inside the body for effective targeting
- Discuss limitations of oncology-based animal models for autoimmune settings and examine strategies with gamma delta T-cells to validate lymphoid tissue targeting, depletion efficacy, and safety in the absence of conventional cytokine-driven biomarkers

15.30 **Chair's Closing Remarks**

15.35 **End of Conference Day Two**

"Clear presentations, diverse topics, great setting for networking after the speed dates and lovely organization"

Merus

+44 (0)20 3141 8700 info@hansonwade.com
www.cell-engager-europe.com

Partner With Us

T-Cell Engager Therapeutics Summit EUROPE
9-11th December 2025 | London, UK

Your Global Platform to Foster New & Existing Relationships within the Rapidly Expanding Cell Engager Therapeutics Field

The **T-Cell Engager Therapeutics Summit Europe** is the region's only dedicated meeting bringing together global biopharma leaders to accelerate the next generation of T-cell engagers in **oncology** and beyond. With rapid progress in design, target selection, and translational strategies, this summit unites **drug developers and technology innovators** to overcome preclinical limitations, reduce toxicities, and unlock durable responses in both **solid tumours and hematologic cancers**, with growing applications in **autoimmune disease**.

Partnering with the T-Cell Engager Therapeutics Summit Europe provides a unique opportunity to:

Position your company as a leader in supporting the development of **next-generation TCEs** across oncology and autoimmunity.

Showcase your antibody discovery expertise to optimise **CD3 affinity**, **tumour antigen selectivity**, and co-stimulatory integration for enhanced safety and efficacy.

Demonstrate cutting-edge preclinical modelling platforms that improve the **translatability of TCEs** from bench to bedside, addressing challenges such as hyperactivated T cells and unrealistic tumour clearance.

Highlight your cytokine assays and profiling solutions to enable developers to accurately assess **CRS risk**, **immune activation**, and **safety margins** earlier in development.

Engage directly with decision-makers – from **CSOs**, **VPs**, and **R&D leaders** at top biopharma actively seeking partners to accelerate discovery, optimise TCE design, and expand therapeutic applications.

With **T-cell engagers driving the next era of cancer immunotherapy**, this meeting is your gateway to shaping the competitive landscape, forming long-term partnerships, and securing your role at the forefront of innovation.

Seniority of Attendees

- CXO 10%
- VP 18%
- Director 32%
- Head 7%
- Scientist 30%
- Academic 1%
- Other 2%

Types of Companies Attending



- Drug Developers
- Academic & Research Institutes
- Solution Providers & Others

Statistics Taken from 7th T-Cell Engager Therapeutics Summit (Boston, MA)

Get Involved

Edward O'Keefe
Partnerships Director
Tel: +44 (0)20 3141 8700
Email: sponsor@hansonwade.com

Ready to Register?

3 Easy Ways to Book

www.cell-engager-europe.com/register

Tel: +44 (0)20 3141 8700

Email: info@hansonwade.com

Unlock the Next Wave of Oncology TCE Design
Discover how innovators are engineering logic-gated, conditional, and co-stimulatory TCEs to enhance tumour specificity, overcome antigen escape, and expand efficacy into solid tumours while minimising systemic toxicities such as CRS.

Advance Preclinical Models & Translational Strategies
Learn how improved in vitro and in vivo models are being deployed to better predict clinical outcomes, tackle challenges such as hyperactivated T cells and unrealistic tumour clearance, and inform smarter trial design for hematologic and solid tumour indications.

Expand Beyond Oncology Into Autoimmunity
Gain first-hand insights from Cullinan, IN8Bio, and Cue Biopharma on pioneering the use of TCEs in autoimmune diseases, uncovering the unique trial considerations versus oncology, and strategies to selectively target pathogenic B cells and T cell subsets.

Drug Developers	Register & Pay By Friday, 19 September	On the Door Price
Conference + Workshop Day	£2,497.00	£3,597.00
Conference Only	£1,899.00	£2,599.00

Academic & Research Institutes**	Register & Pay By Friday, 19 September	On the Door Price
Conference + Workshop Day	£1,897.00	£2,997.00
Conference Only	£1,499.00	£2,199.00

Solution & Service Providers	Register & Pay By Friday, 19 September	On the Door Price
Conference + Workshop Day	£3,197.00	£4,297.00
Conference Only	£2,399.00	£3,099.00

If you are a UK or EU-based company, you may be subject to a 20% VAT in addition to the price advertised. If you qualify for a reverse charge, you will have the option to provide your VAT number and the charge will be automatically deducted at checkout.

*To qualify for the drug developer rate your company must have a public drug pipeline and not provide fee-based services. Please visit the website for full pricing options or email info@hansonwade.com

**To qualify for academic and research rate you must be full time academic. Please visit the website for full pricing options or email info@hansonwade.com

Do you work for a Not-for-Profit organization? Email us at info@hansonwade.com to inquire about attending

Team Discounts***

- **10% discount – 2 Attendees**
- **15% discount – 3 Attendees**
- **20% discount – 4+ Attendees**

***Please note that discounts are only valid when two or more delegates from one company book and pay at the same time.

Discounts cannot be used in conjunction with any other offer or discount. Only one discount offer may be applied to the current pricing rate.

Contact: register@hansonwade.com

Venue

Park Plaza Victoria
239 Vauxhall Bridge Road, London, SW1V 1EQ
www.radissonhotels.com/en-us/hotels/park-plaza-victoria-london

TERMS & CONDITIONS

Full payment is due on registration. Cancellation and Substitution Policy: Cancellations must be received in writing. If the cancellation is received more than 14 days before the conference attendees will receive a full credit to a future conference. Cancellations received 14 days or less (including the fourteenth day) prior to the conference will be liable for the full fee. A substitution from the same organization can be made at any time.

Changes to Conference & Agenda: Every reasonable effort will be made to adhere to the event programme as advertised. However, it may be necessary to alter the advertised content, speakers, date, timing, format and/or location of the event. We reserve the right to amend or cancel any event at any time. Hanson Wade is not responsible for any loss or damage or costs incurred as a result of substitution, alteration, postponement or cancellation of an event for any reason and including causes beyond its control including without limitation, acts of God, natural disasters, sabotage, accident, trade or industrial disputes, terrorism or hostilities.

Data Protection: The personal information shown and/or provided by you will be held in a database. It may be used to keep you up to date with developments in your industry. Sometimes your details may be obtained or made available to third parties for marketing purposes. If you do not wish your details to be used for this purpose, please write to: Hanson Wade Ltd, Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH, United Kingdom